Teknova to Report First Quarter 2023 Financial Results on May 10, 2023
Teknova (Nasdaq: TKNO) announced it will report Q1 financial results for the period ending March 31, 2023, on May 10, 2023, after market close. A conference call and webcast will follow at 5:00 p.m. ET on the same day, accessible via the company's Investor Relations page. Founded in 1996 and headquartered in Hollister, California, Teknova specializes in producing critical reagents for life sciences, supporting cell and gene therapy, molecular diagnostics, and synthetic biology. The company offers customizable solutions for various workflows, emphasizing fast turnaround of high-quality products, which are vital for therapy discovery and development.
- Teknova will provide financial results, which can offer insights into business performance.
- The company supports critical life sciences sectors, indicating potential for revenue growth.
- None.
HOLLISTER, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, following the close of market.
Teknova will host a webcast and conference call on Wednesday, May 10, 2023, beginning at 5:00 p.m. Eastern Time. Participants can access the live webcast on the Investor Relations section of the Teknova website and at this link: https://edge.media-server.com/mmc/p/tquygjuv. To receive a PIN number for dial in, participants can register for the webcast via this link: https://register.vevent.com/register/BIaab243465e1942deb84daf92e4eb35d8. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.
FAQ
When will Teknova announce its Q1 2023 financial results?
What time is the Teknova Q1 2023 earnings call?
Where can I listen to the Teknova Q1 2023 earnings call?
What is Teknova's focus in the life sciences industry?
